ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes
May 24 2017 - 5:00AM
Business Wire
ICON & Regeneron recognised for
demonstrating successful collaboration between pharma &
CRO
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, and Regeneron
Pharmaceuticals, Inc., a leading science-based biopharmaceutical
company that discovers, invents, develops, manufactures and
commercializes medicines for the treatment of serious medical
conditions, have won the Partnership in Clinical Research award at
the 2017 PharmaTimes International Clinical Researcher of the Year
Awards, which took place in London on 18th May. The companies were
represented by Agnieszka Szpineta of ICON and Jacquie Kuritzky of
Regeneron.
Designed to challenge, recognise and reward the talent and
passion of industry and academic researchers, the PharmaTimes
International Clinical Researcher of the Year Awards is the only
global competition that tests the competencies and skills of
clinical research professionals in a real-life challenge against
their peers. Entrants in 2017 came from 48 different countries and
were subject to a rigorous 3-step entry process, judged by a panel
of senior industry leaders. With a co-operation that started in
2010, the project management professionals from ICON and Regeneron
were judged to have demonstrated the best skills and collaborative
qualities for successful partnerships. The Partnership in Clinical
Research Award is the second PharmaTimes award that ICON has won in
2017. In April, two ICON CRAs won awards in the US Clinical
Researcher of the Year competition.
Commenting on the award, ICON Chief Executive Officer, Dr. Steve
Cutler, said: “We are very proud to receive further industry
recognition for having the best skills, expertise and collaborative
qualities that drive successful clinical research partnerships. We
work hard to ensure the continuous development of our people and in
promoting a culture that is based on teamwork, trust and a
commitment to helping our customers solve complex development
challenges. We look forward to continuing our partnership with
Regeneron and to helping them bring to market medicines that will
improve the lives of patients with cancer, chronic pain,
cardiovascular disease and skin disorders. “
Bari Kowal, Head of Global Clinical Operations at Regeneron,
stated, “Regeneron is pleased to receive this recognition together
with ICON. As a science-driven biotechnology company, Regeneron has
been dedicated and passionate for nearly 30 years to cultivate an
innovative and collaborative approach to drug development. We
maintain a priority and commitment to preserving an environment
that empowers people to feel invested and proud of what we are
hoping to accomplish. Our collaboration with ICON has been
extremely successful to date and represents an exciting synergy to
turn ground breaking science into medicines that have the potential
to bring new hope to patients with a range of serious
diseases.”
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 87 locations in 38 countries and has approximately
12,300 employees. Further information is available at
www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170524005077/en/
ICON Media ContactCamille FrederixWeber ShandwickTel: +44
(0)207 067 0272Email: cfrederix@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024